Evidence map›Paper›PMID 24930007›Full record

ArticleMedical oncology (Northwood, London, England)2014

URG11 predicts poor prognosis of pancreatic cancer by enhancing epithelial-mesenchymal transition-driven invasion.

Wei Peng, Jun Zhang, Jie Liu

Abstract read
PubMed Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. URG11 promotes proliferation and induced apoptosis of LNCaP cells.International journal of molecular medicine · 2019
    Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Wei PengDepartment of Digestive Diseases, Huashan Hospital, Fudan University, No. 12 Wulumuqi Road, Shanghai, 200040, China.
Jun Zhang
Jie Liu
Fudan University · CNHuashan Hospital · CNShanghai Medical College of Fudan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The poor prognosis and high recurrent rate of pancreatic cancer (PC) necessitates the discovery of new predictive markers of PC invasion and prognosis. In this study, we evaluated the expression pattern of up-regulated gene 11 (URG11) in a tissue microarray with 18 pairs of PC and adjacent normal tissues. It was shown that URG11 was significantly up-regulated in PC tissues. High expression levels of URG11 were detected in all PC specimens, but were rarely detected in adjacent non-tumorous tissues. In addition, high expression of URG11 was correlated to poor prognosis. Furthermore, it was discovered that URG11 was correlated to epithelial-mesenchymal transition (EMT) markers and clinical pathological parameters indicative of high PC invasion, while knockdown of URG11 significantly changed the expression pattern of EMT markers and decreased the invasion of PC cells. These findings indicate that URG11 might enhance the invasion of PC by inducing EMT and thus lead to poor PC prognosis. Thus, URG11 has the potential to be a new predictive biomarker of PC invasion and prognosis, which may help in the diagnosis and treatment of PC patients.

Indexed as

AgedBiomarkers, TumorCase-Control StudiesEpithelial-Mesenchymal TransitionFemaleGene Expression Regulation, NeoplasticHumansKaplan-Meier EstimateMaleMiddle AgedPancreatic NeoplasmsPrognosisTrans-ActivatorsUp-RegulationBiomarkers, TumorTrans-ActivatorsVWCE protein, human

Identifiers

PMID24930007
OpenAlexW2073416532

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.